Amyloid-β induces lipid droplet-mediated microglial dysfunction via the enzyme DGAT2 in Alzheimer’s disease

Probably not a substantial claim: may not pass S3 (load-bearing).

Cellular lipids are important for immune cell modulation and signaling.

“are important for immune cell modulation and signaling23”

• cites [23] Cantuti-Castelvetri, 2018, Defective cholesterol clearance limits remyelination in the aged central nervous system, Science sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

Several AD-risk genes such as TREM2, APOE, ABCA7, ABCA1, and CLU are directly related to lipid metabolism.

“Several AD-risk genes such as TREM2, APOE, ABCA7, ABCA1, and CLU are directly related to lipid metabolism.26,27,28,29,30,31”

• cites [26] Wang, 2015, TREM2 lipid sensing sustains the microglial response in an Alzheimer’s disease model, Cell sourceSupported
• cites [27] Fitz, 2021, Phospholipids of APOE lipoproteins activate microglia in an isoform-specific manner in preclinical models of Alzheimer’s disease, Nat. Commun. sourcePartly supported

  The Introduction (page not provided) identifies APOE and TREM2 as AD-risk genes, describes APOE as a lipid transporter, and says TREM2 recognizes lipoproteins. It also describes ABCA1 transferring phospholipids and cholesterol to APOE. The passages from our copy do not establish the claimed lipid-metabolism connection for ABCA7 or CLU, or explicitly identify ABCA1 as an AD-risk gene. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [28] Bosch-Queralt, 2021, Diet-dependent regulation of TGFβ impairs reparative innate immune responses after demyelination, Nat. Metab. sourcePartly supported

  The Results sections on LXR signalling and TREM2 link APOE, ABCA1, and TREM2 to cholesterol transport or lipid metabolism (page numbers are not available in our copy). The paper does not establish that the listed genes are Alzheimer’s disease risk genes, and the passages found do not address ABCA7 or CLU. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [29] Gouna, 2021, TREM2-dependent lipid droplet biogenesis in phagocytes is required for remyelination, J. Exp. Med. sourcePartly supported

  The Introduction links TREM2 to lipid metabolism, and the General discussion identifies apolipoprotein E as involved in cholesterol efflux. The passages do not establish that the listed genes are AD-risk genes or address the lipid-metabolism roles of ABCA7, ABCA1, and CLU; this paper studies remyelination rather than AD risk. (LLM, conf=0.86)

  Experimental — accuracy not yet measured
• cites [30] Andreone, 2020, Alzheimer’s-associated PLCγ2 is a signaling node required for both TREM2 function and the inflammatory response in human microglia, Nat. Neurosci. sourceNot checked — no full text of the source
• cites [31] Nugent, 2020, TREM2 Regulates Microglial Cholesterol Metabolism upon Chronic Phagocytic Challenge, Neuron sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

GWAS identified many AD risk genes related to the immune response and microglia, including phagocytosis genes such as CD33 and TREM2.

“Genome-wide association studies (GWAS) identified many AD risk genes related to the immune response and microglia, including those implicated in phagocytosis, such as CD33 and TREM24,5,6,7,8.”

• cites [4] Bertram, 2008, Genome-wide Association Analysis Reveals Putative Alzheimer’s Disease Susceptibility Loci in Addition to APOE, Am. J. Hum. Genet. sourceNot checked — no full text of the source
• cites [5] Hollingworth, 2011, Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease, Nat. Genet. sourcePartly supported

  The paper reports a GWAS association for CD33 and describes several AD susceptibility loci as having putative immune functions (Abstract; page not provided). It links ABCA7 to microglia and phagocytosis, but describes CD33 as an endocytic receptor, not specifically a phagocytosis gene. A search of our copy found no mention of TREM2, so this source does not support that example. (LLM, conf=0.90)

  Experimental — accuracy not yet measured
• cites [6] Naj, 2011, Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease, Nat. Genet. sourcePartly supported

  The GWAS findings (section labeled Abstract; page unavailable) identify several late-onset Alzheimer’s disease risk loci and specifically confirm CD33. Our copy does not identify TREM2 or describe these loci as microglial, immune-response, or phagocytosis genes; searches for those terms found no supporting passage. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [7] Guerreiro, 2013, TREM2 Variants in Alzheimer’s Disease, N. Engl. J. Med. sourcePartly supported

  The introductory passage lists CD33 among Alzheimer’s risk loci identified by GWAS, and the Discussion links TREM2 in microglia to phagocytosis. But the Methods (Study Design) say this paper identified the TREM2 variants through exome or full-genome sequencing; GWAS data were used afterward to confirm an association, not to identify TREM2 as the claim states. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [8] Jonsson, 2013, Variant of TREM2 Associated with the Risk of Alzheimer’s Disease, N. Engl. J. Med. sourcePartly supported

  The Discussion reports Alzheimer’s risk variants in several inflammation-related genes, including CD33, and links TREM2 in microglia to phagocytosis. The Results report a genomewide association for a TREM2 variant. Our copy describes CD33 as a myeloid cell-surface receptor but does not establish its role in phagocytosis, so that part of the claim is unsupported. (LLM, conf=0.86)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Reactive microglia form a physical barrier believed to restrict plaque propagation.

“form a physical barrier believed to restrict plaque propagation13,14”

• cites [13] Condello, 2015, Microglia constitute a barrier that prevents neurotoxic protofibrillar Aβ42 hotspots around plaques, Nat. Commun. sourceSupported
• cites [14] Yuan, 2016, TREM2 Haplodeficiency in Mice and Humans Impairs the Microglia Barrier Function Leading to Decreased Amyloid Compaction and Severe Axonal Dystrophy, Neuron sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

During early stages of AD, microglia contribute to Aβ clearance.

“During early stages of AD, microglia contribute to Αβ clearance15”

• cites [15] Heneka, 2015, Neuroinflammation in Alzheimer’s disease, Lancet Neurol. sourcePartly supported

  The ‘Microglial Aβ clearance mechanisms’ subsection says microglia engulf Aβ fibrils by phagocytosis, supporting their contribution to clearance. ‘Modulating innate immunity’ says microglial roles vary by disease stage, but the passages do not establish that this clearance specifically occurs during the early stages of AD. Page numbers are unavailable in our copy. (LLM, conf=0.82)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Accumulation of amyloid-beta is a histological hallmark of the AD brain.

“Accumulation of amyloid-beta (Αβ) is a histological hallmark of the AD brain1.”

• cites [1] Serrano-Pozo, 2011, Neuropathological alterations in Alzheimer disease, Cold Spring Harb. Perspect. Med. sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

Single-cell RNA sequencing identified gene signatures characteristic of protective and dysfunctional microglial subpopulations in AD.

“Single-cell RNA sequencing identified gene signatures characteristic of protective and dysfunctional microglial subpopulations in AD9,10.”

• cites [9] Keren-Shaul, 2017, A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease, Cell sourcePartly supported

  The Results describe single-cell RNA sequencing that identified distinct disease-associated microglia (DAM) states and their gene-expression markers in an AD mouse model. The Discussion calls DAM a protective microglial subtype, but the cited passages do not identify a separate dysfunctional microglial subpopulation. Page numbers are unavailable in our copy. (LLM, conf=0.85)

  Experimental — accuracy not yet measured
• cites [10] Krasemann, 2017, The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases, Immunity sourcePartly supported

  The Results section on AD plaques identifies homeostatic and dysfunctional microglial subsets and reports gene-expression signatures for them. However, STAR*METHODS describes RNA sequencing of 1,000 FACS-sorted microglia, not single-cell RNA sequencing. The paper also does not characterize the homeostatic subset as protective. (LLM, conf=0.90)

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim.

Sustained inflammation contributes to neurodegeneration.

“but sustained inflammation contributes to neurodegeneration12”

• cites [12] Wyss-Coray, 2012, Inflammation in Alzheimer disease-A brief review of the basic science and clinical literature, Cold Spring Harb. Perspect. Med. sourcePartly supported

  The Conclusions (page not provided) say increased peripheral inflammation leads to more neurodegeneration in animal models and possibly in Alzheimer disease. That supports a contribution from inflammation, but the review also describes inflammatory responses as potentially protective; it does not establish that sustained inflammation generally causes neurodegeneration. (LLM, conf=0.82)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Multiple sporadic AD risk variants were identified in microglial transcriptional enhancer regions in humans.

“multiple sporadic AD risk variants were identified in microglial transcriptional enhancer regions in humans11”

• cites [11] Nott, 2019, Brain cell type–specific enhancer–promoter interactome maps and disease-risk association, Science sourceSupported

May combine two claims.

Increased pro-inflammatory gene expression in response to accumulating Aβ in older AD mice leads to decreased microglial Aβ clearance receptors or Aβ-degrading enzymes, thereby promoting further Aβ accumulation.

“Increased pro-inflammatory gene expression in response to accumulating Αβ in older AD mice leads to decreased microglial Αβ clearance receptors or Αβ-degrading enzymes, thereby promoting further Αβ accumulation16.”

• cites [16] Hickman, 2008, Microglial dysfunction and defective β-amyloid clearance pathways in aging alzheimer’s disease mice, J. Neurosci. sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

In the AD brain, reactive microglia cluster around Aβ plaques.

“In the AD brain, reactive microglia cluster around Aβ plaques12”

• cites [12] Wyss-Coray, 2012, Inflammation in Alzheimer disease-A brief review of the basic science and clinical literature, Cold Spring Harb. Perspect. Med. sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

5xFAD mice develop prominent gliosis, inflammation, neuronal loss, behavioral impairments, and sex-distinct systemic metabolic changes.

“5xFAD mice also develop prominent gliosis, inflammation, neuronal loss, behavioral impairments, and sex-distinct systemic metabolic changes39,38,40.”

• cites [39] Oblak, 2021, Comprehensive Evaluation of the 5XFAD Mouse Model for Preclinical Testing Applications: A MODEL-AD Study, Front. Aging Neurosci. sourceSupported
• cites [38] Oakley, 2006, Intraneuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: Potential factors in amyloid plaque formation, J. Neurosci. sourcePartly supported

  The sections on rapid amyloid pathology, neuroinflammation, neuron loss, and spatial memory deficits report gliosis, inflammation, neuron loss, and behavioral impairment in 5XFAD mice (page numbers unavailable). The paper does not report sex-distinct systemic metabolic changes; its sex-related observations concern cerebral amyloid levels and synaptophysin. (LLM, conf=0.90)

  Experimental — accuracy not yet measured
• cites [40] Merlini, 2019, Fibrinogen Induces Microglia-Mediated Spine Elimination and Cognitive Impairment in an Alzheimer’s Disease Model, Neuron sourcePartly supported

  The Results section reports hippocampal neuronal loss, microglial activation, and severe learning and memory impairments in 5XFAD mice, supporting much of the sentence. Our copy does not establish sex-distinct systemic metabolic changes; the Methods state that only male mice were used for behavioral experiments. Page numbers were not available in the indexed passages. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Human iPSC-derived microglia were enriched in lipid droplets in a chimeric mouse model of AD.

“human iPSC-derived microglia were enriched in LDs in a chimeric mouse model of AD37”

• cites [37] Claes, 2021, Plaque-associated human microglia accumulate lipid droplets in a chimeric model of Alzheimer’s disease, Mol. Neurodegener. sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

Inflammatory triggers like lipopolysaccharide, fatty acids, and aging promote lipid droplet accumulation in primary microglial cells and cell lines.

“Inflammatory triggers like lipopolysaccharide (LPS)35,19, fatty acids36, and aging20 promote LD accumulation in primary microglial cells and cell lines.”

• cites [35] Khatchadourian, 2012, Dynamics and regulation of lipid droplet formation in lipopolysaccharide (LPS)-stimulated microglia, Biochim. Biophys. Acta sourceNot checked — no full text of the source
• cites [19] Tremblay, 2016, Remodeling of lipid bodies by docosahexaenoic acid in activated microglial cells, J. Neuroinflammation sourcePartly supported

  The Results (Remodeling of lipid bodies; page unavailable) show that LPS increased lipid vacuoles in the N9 microglial cell line, but distinguish those vacuoles from lipid droplets, which were rare under both control and LPS-only conditions. This source therefore supports LPS-related lipid-body accumulation, not the more specific claim that LPS alone promotes lipid-droplet accumulation. The sentence assigns fatty acids and aging to other citations. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [36] Urso, 2021, Palmitic acid lipotoxicity in microglia cells is ameliorated by unsaturated fatty acids, Int. J. Mol. Sci. sourceSupported
• cites [20] Marschallinger, 2020, Lipid-droplet-accumulating microglia represent a dysfunctional and proinflammatory state in the aging brain, Nat. Neurosci. sourceSupported

Classified as probably not a substantial claim.

5xFAD mice progressively accumulate extensive Aβ plaques especially in the subiculum and deep cortical layers starting around 2-3 months of age.

“which progressively accumulates extensive Aβ plaques (especially in the subiculum and deep cortical layers) starting around 2–3 months of age”

• cites [38] Oakley, 2006, Intraneuronal β-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: Potential factors in amyloid plaque formation, J. Neurosci. sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

DGAT2 is evolutionarily conserved across eukaryotes and has the predominant and ancient function of mediating triacylglycerol synthesis from fatty acids.

“The DGAT2 enzyme is evolutionarily conserved across eukaryotes and has the predominant and ancient function of mediating TG synthesis from fatty acids50.”

• cites [50] Chitraju, 2019, The triglyceride synthesis enzymes DGAT1 and DGAT2 have distinct and overlapping functions in adipocytes, J. Lipid Res. sourceSupported

May combine two claims.

DGAT2 is localized around lipid droplets where it is required for triacylglycerol synthesis.

“DGAT2 is localized around LDs where it is required for TG synthesis51,52,53.”

• cites [51] Wilfling, 2013, Triacylglycerol synthesis enzymes mediate lipid droplet growth by relocalizing from the ER to lipid droplets, Dev. Cell sourceSupported
• cites [52] Kuerschner, 2008, Imaging of lipid biosynthesis: How a neutral lipid enters lipid droplets, Traffic sourceNot checked — no full text of the source
• cites [53] Stone, 2009, The endoplasmic reticulum enzyme DGAT2 is found in mitochondria-associated membranes and has a mitochondrial targeting signal that promotes its association with mitochondria, J. Biol. Chem. sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

Female microglia exhibit higher pro-inflammatory responses compared to age-matched male cells.

“with female cells exhibiting higher pro-inflammatory responses compared to age-matched male cells.67,68”

• cites [67] Murtaj, 2019, Age and Sex Influence the Neuro-inflammatory Response to a Peripheral Acute LPS Challenge, Front. Aging Neurosci. sourcePartly supported

  The Discussion reports a stronger pro-inflammatory response to LPS in aged female than aged male mouse brains, and the Results identify higher levels of particular inflammatory transcripts in aged females. The claim omits the aged-mouse and acute LPS-challenge conditions and presents a brain-level finding as a general property of female microglial cells; the Discussion also describes adult male microglia as more poised to inflammatory reactions. (LLM, conf=0.87)

  Experimental — accuracy not yet measured
• cites [68] Doyle, 2017, Sex differences in microglia activity within the periaqueductal gray of the rat: A potential mechanism driving the dimorphic effects of morphine, J. Neurosci. sourcePartly supported

  The Subjects section specifies age-matched male and female rats, and Experiment 3b reports a greater pro-inflammatory response in female than male vlPAG after LPS challenge. But cytokine mRNA was measured in vlPAG tissue, not isolated microglia; the paper does not establish that female microglial cells themselves produced the higher response. It also limits the finding to this brain region and immune-challenge condition. (LLM, conf=0.85)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Sex differences in microglia have been reported in both rodents and humans.

“Sex differences in microglia have been reported in both rodents and humans66”

• cites [66] Han, 2021, Uncovering sex differences of rodent microglia, J. Neuroinflammation sourcePartly supported

  The Abstract and the section on microglial morphology and numbers through development report sex differences in rodent microglia. The review focuses on rodents; the passages found do not report corresponding differences in human microglia, so the human part of the claim is unsupported by this paper. (LLM, conf=0.87)

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim. May combine two claims.

Microglia engulf and degrade Aβ.

“Microglia engulf and degrade Aβ74,75”

• cites [74] Liu, 2010, CX3CR1 in microglia regulates brain amyloid deposition through selective protofibrillar amyloid-β phagocytosis, J. Neurosci. sourcePartly supported

  The Results (page unavailable) show that microglia phagocytose oligomeric and protofibrillar Aβ, supporting “engulf.” The same passage says this material “may be targeted for degradation” because it is found in phagolysosomes; it does not establish degradation as a fact. The Discussion also reports that microglia could not remove fibrillar amyloid from preexisting plaques in vivo. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [75] Mandrekar, 2009, Microglia mediate the clearance of soluble aβ through fluid phase macropinocytosis, J. Neurosci. sourceSupported

May combine two claims.

Microglial phagocytic capacity declines with aging, chronic exposure to Aβ, and during sustained inflammation in the AD brain.

“their phagocytic capacity declines with aging, chronic exposure to Αβ, and during sustained inflammation in the AD brain76,16,17.”

• cites [76] Njie, 2012, Ex vivo cultures of microglia from young and aged rodent brain reveal age-related changes in microglial function, Neurobiol. Aging sourcePartly supported

  The Discussion (page unavailable) reports a 2- to 4-fold age-related decrease in Aβ internalization by microglia from aged mice, supporting the aging portion of the claim. The paper does not show that chronic Aβ exposure or sustained inflammation in the AD brain causes a decline in phagocytic capacity; it discusses AD as a possible implication of its age-related findings. (LLM, conf=0.90)

  Experimental — accuracy not yet measured
• cites [16] Hickman, 2008, Microglial dysfunction and defective β-amyloid clearance pathways in aging alzheimer’s disease mice, J. Neurosci. sourcePartly supported

  The Discussion reports declining Aβ-clearing ability as PS1-APP mice age and AD-like pathology progresses. The Results show reduced Aβ uptake after TNFα treatment and increased inflammatory cytokines in older mice with continued Aβ deposition. The paper does not establish chronic Aβ exposure as a separate cause of declining phagocytosis or demonstrate the claimed decline in human AD brains; its direct evidence is from mice and cultured mouse microglia. Page numbers are unavailable in our copy. (LLM, conf=0.84)

  Experimental — accuracy not yet measured
• cites [17] Krabbe, 2013, Functional Impairment of Microglia Coincides with Beta-Amyloid Deposition in Mice with Alzheimer-Like Pathology, PLoS One sourcePartly supported

  The Results section reports reduced microglial phagocytosis where Aβ plaques were present in Alzheimer-like mice, but normal capacity in plaque-free regions, including as the mice aged. The Discussion proposes sustained inflammation as a possible explanation rather than establishing it as a cause. The paper therefore supports plaque-associated decline, not the full claim that aging, chronic Aβ exposure, and sustained inflammation each cause decline in the AD brain. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

The hippocampal subicular regions of 5xFAD mice and hippocampi from individuals with AD are sites of the earliest atrophy seen during AD pathogenesis.

“which are the sites of the earliest atrophy seen during AD pathogenesis.65”

• cites [65] Carlesimo, 2015, Atrophy of presubiculum and subiculum is the earliest hippocampal anatomical marker of Alzheimer’s disease, Alzheimers. Dement. (Amst) sourcePartly supported

  The Abstract Conclusions and Discussion identify the presubiculum and subiculum as sites of prevalent atrophy from early AD phases in human patients. The study examined people with MCI or AD and healthy controls, not 5xFAD mice, so it does not support the mouse portion of the claim. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

Classified as probably not a substantial claim. May combine two claims.

APP is a marker of axonal degeneration and accumulates in presynaptic terminals, indicative of dystrophic neurons surrounding amyloid plaques.

“Previous studies have established APP as a marker of axonal degeneration54,55 and demonstrated its accumulation in presynaptic terminals, indicative of dystrophic neurons surrounding amyloid plaques.56”

• cites [54] Mabrouk, 2023, Most dystrophic neurites in the common 5xFAD Alzheimer mouse model originate from axon terminals, Neurobiol. Dis. sourceNot checked — no full text of the source
• cites [55] Illán-Gala, 2019, APP-derived peptides reflect neurodegeneration in frontotemporal dementia, Ann. Clin. Transl. Neurol. sourcePartly supported

  The Discussion reports that CSF APP-derived peptides may serve as neurodegeneration biomarkers in FTLD, supporting the marker idea in a narrower form. It does not establish APP itself as a marker specifically of axonal degeneration. The separate claim about accumulation near amyloid plaques is attached to citation 56, not to this source. (LLM, conf=0.85)

  Experimental — accuracy not yet measured
• cites [56] Jordà-Siquier, 2022, APP accumulates with presynaptic proteins around amyloid plaques: A role for presynaptic mechanisms in Alzheimer’s disease?, Alzheimers Dement. sourcePartly supported

  The Results report APP accumulations around amyloid plaques enriched in presynaptic proteins, and the study conclusions describe presynaptic APP within dystrophic axons (page numbers unavailable). However, the paper places the accumulations at axon terminals only presumptively; it does not demonstrate that they are in presynaptic terminals. The axonal-degeneration marker claim is attached to citations 54 and 55, not this citation. (LLM, conf=0.85)

  Experimental — accuracy not yet measured

May combine two claims.

Injured neurons and oligodendrocytes have a low capacity for consuming FFAs and sequestering them into lipid droplets, making them more vulnerable to lipid-induced cytotoxicity in chronic inflammation.

“Injured neurons and oligodendrocytes have a low capacity for consuming FFAs and sequestering them into LDs61, making them more vulnerable to lipid-induced cytotoxicity in chronic inflammation62,63.”

• cites [61] Schönfeld, 2013, Why does brain metabolism not favor burning of fatty acids to provide energy? Reflections on disadvantages of the use of free fatty acids as fuel for brain, J. Cereb. Blood Flow Metab. sourceNot checked — no full text of the source
• cites [62] Sultana, 2013, Lipid peroxidation triggers neurodegeneration: A redox proteomics view into the Alzheimer disease brain, Free Radic. Biol. Med. sourcePartly supported

  Section 1, “Lipid peroxidation and neurodegeneration” (page unavailable), says lipid peroxidation damages neuronal membranes and produces compounds that cause cellular damage. It does not establish the claimed vulnerability of oligodendrocytes or place that damage in chronic inflammation. The separate claim about FFA consumption and lipid-droplet sequestration is attached to citation 61, not to this source. (LLM, conf=0.83)

  Experimental — accuracy not yet measured
• cites [63] Ioannou, 2019, Neuron-Astrocyte Metabolic Coupling Protects against Activity-Induced Fatty Acid Toxicity, Cell sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Female microglia upregulate genes related to metabolic activities like glycolysis and oxidative metabolism, which become more pronounced with aging.

“female microglia upregulate genes related to metabolic activities like glycolysis and oxidative metabolism, which become more pronounced with aging.69”

• cites [69] Cleland, 2024, Altered metabolism and DAM-signatures in female brains and microglia with aging, Brain Res. sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

Subclusters of lipid-associated microglia are enriched in women compared to men.

“Subclusters of lipid-associated microglia were also enriched in women compared to men,72”

• cites [72] Green, 2023, Cellular dynamics across aged human brains uncover a multicellular cascade leading to Alzheimer’s disease, Alzheimers Dement. sourceCould not verify

  The high-resolution cell atlas section (page unavailable) identifies Mic.12 and Mic.13 as lipid-associated microglial subpopulations. The sections on AD-related traits and disease-associated microglia discuss their proportions in relation to pathology and diagnosis, but do not report enrichment in women versus men. Searches for female/male enrichment and sex differences found no passage addressing that comparison. (LLM, conf=0.73)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Late-onset AD (~95% of AD cases) is associated with impaired Aβ clearance.

“Late-onset AD, (~95% of AD cases), is associated with impaired Αβ clearance73.”

• cites [73] Mawuenyega, 2010, Decreased clearance of CNS β-amyloid in Alzheimer’s disease, Science sourcePartly supported

  The paper’s findings passage reports that late-onset AD is associated with impaired clearance of Aβ40 and Aβ42. It describes late-onset AD as far more common than rare genetic cases, but does not give the claimed figure of approximately 95% of AD cases (no page number is available in our copy). (LLM, conf=0.87)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

Reactive astrocytes secrete long-chain saturated FFAs that kill injured neurons and oligodendrocytes in vitro and in vivo.

“Reactive astrocytes secrete long-chain saturated FFAs that kill injured neurons and oligodendrocytes in vitro and in vivo41.”

• cites [41] Guttenplan, 2021, Neurotoxic reactive astrocytes induce cell death via saturated lipids, Nature sourcePartly supported

  The Discussion reports that reactive astrocytes drive neuronal and mature oligodendrocyte death through delivery of FFAs and very-long-chain phosphatidylcholines. Extended Data Figure 7 shows saturated FFA toxicity to cultured oligodendrocytes, while the optic-nerve-crush results concern injured retinal neurons in vivo. The paper does not establish oligodendrocyte death in vivo, and it describes the in-vivo contribution of FFAs and phosphatidylcholines as partial rather than attributing it to FFAs alone. (LLM, conf=0.88)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

Restoration of microglial phagocytosis improves cognitive function in aged mice and promotes a homeostatic microglial transcriptional signature.

“restoration of microglial phagocytosis improved cognitive function in aged mice and promoted a homeostatic microglial transcriptional signature78.”

• cites [78] Pluvinage, 2019, CD22 blockade restores homeostatic microglial phagocytosis in ageing brains, Nature sourceSupported

May combine two claims.

Genetic deletion of any of these receptors in mouse models of AD results in less compact/more diffuse plaques, and increased neuritic dystrophy around Aβ deposits.

“Genetic deletion of any of these receptors in mouse models of AD resulted in less compact/more diffuse plaques, and increased neuritic dystrophy around Αβ deposits14,79.”

• cites [14] Yuan, 2016, TREM2 Haplodeficiency in Mice and Humans Impairs the Microglia Barrier Function Leading to Decreased Amyloid Compaction and Severe Axonal Dystrophy, Neuron sourceSupported
• cites [79] Huang, 2021, Microglia use TAM receptors to detect and engulf amyloid β plaques, Nat. Immunol. sourcePartly supported

  The Results (“TAM-dependent phagocytosis and shaping of plaques”; page unavailable) report more diffuse plaques and increased markers of dystrophic neuronal membranes after combined Axl and Mertk deletion in APP/PS1 mice. But the paper does not show these outcomes after deletion of any one receptor: in “Dense-core plaque burden in the absence of TAM signaling,” Mertk deletion largely reproduces the reduction in dense-core plaques, whereas Axl deletion does not reduce cortical plaque burden. (LLM, conf=0.90)

  Experimental — accuracy not yet measured

May combine two claims.

The phagocytic function of macrophages is dependent on FFAs generated upon degradation of lipid droplets, suggesting that lipid droplet accumulation limits the phagocytic capacity of tissue-resident macrophages.

“the phagocytic function of macrophages was found dependent on FFAs generated upon degradation of LDs, suggesting that LD accumulation somehow limits the phagocytic capacity of tissue-resident macrophages81.”

• cites [81] Chandak, 2010, Efficient phagocytosis requires triacylglycerol hydrolysis by adipose triglyceride lipase, J. Biol. Chem. sourcePartly supported

  The Introduction and Discussion report that reduced release of fatty acids from lipid-droplet triglycerides impairs phagocytosis, and suggest that accumulated droplets may also contribute. But the Experimental Procedures describe thioglycollate-elicited mouse peritoneal macrophages and bone-marrow-derived macrophages; the paper does not establish the proposed limitation across tissue-resident macrophages generally. (LLM, conf=0.85)

  Experimental — accuracy not yet measured

Probably not a substantial claim: may not pass S3 (load-bearing).

AβpH has been thoroughly characterized in vitro in primary cell culture and in vivo in a previous study.

“AβpH is a pH-sensitive fluorophore conjugate of Aβ1–42 peptide that is generated within our laboratory and has been thoroughly characterized in vitro in primary cell culture as well as in vivo experiments in our previous study.47”

• cites [47] Prakash, 2021, Monitoring phagocytic uptake of amyloid β into glial cell lysosomes in real time, Chem. Sci. sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

Pharmacological inhibition of DGAT2 has consistently shown efficacy in pre-clinical studies demonstrating reduced triacylglycerol synthesis accompanied by reduced expression of genes essential for de novo lipogenesis.

“Further, pharmacological inhibition of DGAT2 has consistently shown efficacy in pre-clinical studies demonstrating reduced TG synthesis accompanied by reduced expression of genes essential for de novo lipogenesis.85”

• cites [85] Amin, 2023, Inhibition of Diacylglycerol Acyltransferase 2 Versus Diacylglycerol Acyltransferase 1: Potential Therapeutic Implications of Pharmacology, Clin. Ther. sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

Prior studies proposed that plaque-associated microglia compact amyloid plaques through receptors implicated in phagocytosis such as TREM2, AXL, and MER.

“Prior studies proposed that these cells compact amyloid plaques through receptors implicated in phagocytosis such as TREM214, (expressed on myeloid cells and associated to increased AD risk)14,8, AXL, and MER79.”

• cites [14] Yuan, 2016, TREM2 Haplodeficiency in Mice and Humans Impairs the Microglia Barrier Function Leading to Decreased Amyloid Compaction and Severe Axonal Dystrophy, Neuron sourceSupported
• cites [8] Jonsson, 2013, Variant of TREM2 Associated with the Risk of Alzheimer’s Disease, N. Engl. J. Med. sourcePartly supported

  The Discussion (page unavailable in our copy) says TREM2 is expressed on microglia and links its expression to amyloid phagocytosis near plaques. It does not say that TREM2 enables microglia to compact plaques. The AXL and MER portion carries a different citation and is not attributed to this source. (LLM, conf=0.88)

  Experimental — accuracy not yet measured
• cites [79] Huang, 2021, Microglia use TAM receptors to detect and engulf amyloid β plaques, Nat. Immunol. sourceSupported

Probably not a substantial claim: may not pass S3 (load-bearing).

The aggregated states of the Aβ1-42 peptides have been thoroughly characterized using atomic force microscopy and western blotting in previous papers.

“The aggregated states of the Aβ1–42 peptides have been thoroughly characterized using atomic force microscopy and western blotting in our previous papers.100,47”

• cites [100] Prakash, 2019, Rapid, Refined, and Robust Method for Expression, Purification, and Characterization of Recombinant Human Amyloid beta 1–42, Methods Protoc. sourceSupported
• cites [47] Prakash, 2021, Monitoring phagocytic uptake of amyloid β into glial cell lysosomes in real time, Chem. Sci. sourcePartly supported

  The Results section (page unavailable) reports AFM characterization of Aβ1–42 oligomers, and the Methods section says the AFM analysis followed previously published protocols. The passages do not establish that previous papers thoroughly characterized the peptides’ aggregated states using both AFM and western blotting; western blotting is not documented in the retrieved passages. (LLM, conf=0.85)

  Experimental — accuracy not yet measured

May combine two claims.

Pharmacologically targeting DGAT2 improves microglial uptake of Aβ and reduces plaque load and neuronal damage in 5xFAD mice.

“Pharmacologically targeting DGAT2 improved microglial uptake of Aβ and reduced plaque load and neuronal damage in 5xFAD mice.”

• Also stated in: § The DGAT2 pathway is required for Aβ-induced lipid droplet formation in AD microglia, and its inhibition rescues microglial phagocytic impairment and reduces plaque load in AD · plain

  “LD+ 5xFAD microglia showed a significant increase (1.41-fold) in AβpH uptake with D2i”

• Also stated in: § The DGAT2 pathway is required for Aβ-induced lipid droplet formation in AD microglia, and its inhibition rescues microglial phagocytic impairment and reduces plaque load in AD · plain

  “animals that received the DGAT2 degrader over a period of 1 week showed a drastic reduction in plaque burden by ~51% in the subicular hippocampal region compared to age-matched vehicle-treated animals”

• AssumptionRests on an assumption: The DGAT2 inhibitor D2i selectively inhibits DGAT2 in microglia without off-target effects on lipid droplet formation or phagocytosis.
• AssumptionRests on an assumption: The DGAT2 degrader selectively degrades DGAT2 in vivo without off-target effects.

May combine two claims.

Very few secretory lipids are differentially regulated with Aβ treatment - none at 1 hour, five at 12 hours, and one at 24 hours.

“We found very few secretory lipids differentially regulated with Aβ treatment –none at 1 hour, five at 12 hours, and one at 24 hours, respectively”

May combine two claims.

The male 5xFAD microglial lipidome shows less variability than the female lipidome, in agreement with more limited variation in LD content in male microglia.

“In contrast, the male lipidome showed less variability (Fig. S1f), in agreement with the more limited variation in LD content in male microglia”

May combine two claims.

In the subiculum, plaque-proximal microglia demonstrate an amoeboid morphology, while plaque-distant cells typically have smaller cell bodies and longer processes.

“In the subiculum, plaque-proximal microglia demonstrated an amoeboid morphology, while plaque-distant cells typically had smaller cell bodies and longer processes”

May combine two claims.

Metabolites like fructose 6-phosphate and lactose are downregulated in 5xFAD microglia compared to WT cells, affecting several metabolic pathways such as the citrate TCA cycle, glutamine and glutamate metabolism, and arginine biosynthesis.

“Metabolites like fructose 6-phosphate and lactose were downregulated in 5xFAD microglia compared to WT cells, affecting several metabolic pathways such as the citrate TCA cycle, glutamine and glutamate metabolism, arginine biosynthesis, etc.”

May combine two claims.

LD+ microglia are predominantly near amyloid plaques, and their numbers decline with distance from them.

“LD+ microglia were predominantly near amyloid plaques, and their numbers declined with distance from them”

May combine two claims.

FFAs are increased at 1 hour and reduced at 24 hours.

“we found that FFAs were indeed increased at 1 hour and reduced at 24 hours”

May combine two claims.

Free fatty acids are the most differentially regulated lipid class, with very long-chain saturated FFAs C20:0, C22:0, and C19:0 being the most upregulated lipids at 1 hour of Aβ exposure.

“FFAs were the most differentially regulated lipid class, with very long-chain saturated FFAs, C20:0, C22:0, and C19:0 being the most upregulated lipids at 1 hour of Aβ exposure”

May combine two claims.

Cells with prolonged Aβ exposure (24 hours) do not maintain their FFA repertoire and instead transition to triacylglycerols being the most differentially regulated lipid class, with TG(52:3), TG(54:3), and TG(52:2) being the most upregulated.

“In contrast, cells with prolonged Aβ exposure (24 hours) did not maintain their FFA repertoire and instead transitioned to TGs being the most differentially-regulated lipid class, with TG(52:3), TG(54:3), and TG(52:2) being the most upregulated”

May combine two claims.

At 12 hours of Aβ treatment, in addition to FFAs, cholesteryl esters are the second most differentially regulated lipid class, with very long chain CEs 20:2, 24:1, and 16:3 being the top upregulated CEs.

“At 12 hours of Aβ treatment, in addition to FFAs, cholesteryl esters (CEs) were the second most differentially regulated lipid class in microglia, with very long chain CEs 20:2, 24:1, and 16:3 being the top upregulated CEs”

May combine two claims.

Human LD+ microglia closer to plaques (0-10μm) contain larger lipid droplets, and their total lipid droplet load decreases progressively with distance from the nearest plaque.

“human LD+ microglia closer to plaques (0–10μm) contained larger LDs, and their total LD load also decreased progressively with distance from the nearest plaque”

• AssumptionRests on an assumption: Human postmortem hippocampal tissue from AD and non-symptomatic controls is representative of in vivo AD microglial lipid droplet phenotype.

May combine two claims.

Distinct LD-laden microglia are found throughout the brain, but more prominently in the hippocampal subicular regions of 5xFAD mice and in hippocampi from individuals with AD.

“We found these distinct LD-laden microglia throughout the brain, but more prominently in the hippocampal subicular regions of 5xFAD mice and in hippocampi from individuals with AD”

May combine two claims.

LD-laden microglia are closely associated with Aβ plaques and exhibit shorter processes and larger cell bodies in both 5xFAD mouse and human AD brains.

“Indeed, LD-laden microglia were closely associated with Aβ plaques and exhibited shorter processes and larger cell bodies in both 5xFAD mouse and human AD brains.”

May combine two claims.

Overall lipid droplet content is increased in both male and female microglia, but female cells show higher abundance of lipid droplet load compared to age-matched male cells.

“Although overall LD content was increased in both male and female microglia, female cells showed higher abundance of LD load compared to age-matched male cells.”

May combine two claims.

There is a significant reduction in Aβ-induced lipid droplets with D2i treatment in WT microglia, confirming that Aβ-induced lipid droplet formation requires the DGAT2 pathway.

“there was a significant reduction in Aβ-induced LDs with D2i treatment in WT microglia, thereby confirming that Aβ-induced LD formation requires the DGAT2 pathway”

• AssumptionRests on an assumption: The DGAT2 inhibitor D2i selectively inhibits DGAT2 in microglia without off-target effects on lipid droplet formation or phagocytosis.

May combine two claims.

Both WT and 5xFAD microglia show a significant decrease in lipid droplets upon D2i treatment in vitro (by 51% and 57%, respectively).

“Both WT and 5xFAD microglia showed a significant decrease in LDs upon D2i treatment in vitro (by 51% and 57%, respectively”

• AssumptionRests on an assumption: The DGAT2 inhibitor D2i selectively inhibits DGAT2 in microglia without off-target effects on lipid droplet formation or phagocytosis.

May combine two claims.

Amyloid exposure directly increased overall lipid droplet load in all microglia in vitro and in vivo, but with sex-dependent variability.

“Our data shows that amyloid exposure directly increased overall LD load in all microglia in vitro and in vivo, but with sex-dependent variability.”

May combine two claims.

LD+ 5xFAD microglia show a significant increase (1.41-fold) in AβpH uptake with D2i, similar to LD+ WT microglia in the presence of the inhibitor.

“LD+ 5xFAD microglia showed a significant increase (1.41-fold) in AβpH uptake with D2i, which was similar to LD+ WT microglia in the presence of the inhibitor”

• AssumptionRests on an assumption: The DGAT2 inhibitor D2i selectively inhibits DGAT2 in microglia without off-target effects on lipid droplet formation or phagocytosis.

May combine two claims.

Plaque-associated microglia progressively accumulate more lipid droplets, and cells with high lipid droplet content are less capable of Aβ phagocytosis.

“We found that plaque–associated microglia progressively accumulated more LDs, and that cells with high LD content were less capable of Aβ phagocytosis.”

May combine two claims.

Administration of DGAT2 degrader directly inside the brain drastically and rapidly reduced lipid droplets, particularly from plaque-associated microglia, but without eliminating lipid droplets completely.

“For example, we found that administration of DGAT2 degrader directly inside the brain drastically and rapidly reduced LDs, particularly from plaque-associated microglia but without eliminating LDs completely.”

• AssumptionRests on an assumption: The DGAT2 degrader selectively degrades DGAT2 in vivo without off-target effects.

May combine two claims.

The study identified a druggable molecule (DGAT2) that regulates lipid droplet accumulation in microglia while also directly impacting their function and the health of nearby neurons.

“Here, we identified one such druggable molecule that regulates LD accumulation in microglia while also directly impacting their function and the health of nearby neurons.”

May combine two claims.

Disrupting DGAT2 alone is sufficient to reduce microglial lipid droplets and restore their phagocytic efficiency.

“Disrupting DGAT2 alone proved sufficient to not only reduce microglial LDs but also restore their phagocytic efficiency”

May combine two claims.

A new DGAT2 protein degrader reduced lipid droplet load in vivo in 11-24-month-old 5xFAD mice and produced a profound reduction of amyloid load (51%) and neurite dystrophy (47%), despite its very brief treatment duration (only 1 week).

“We thus developed a new DGAT2 protein degrader that not only reduced LD load in vivo in 11–24-month-old 5xFAD mice but also produced a profound reduction of amyloid load (51%) and neurite dystrophy (47%), despite its very brief treatment duration (only 1 week).”

• AssumptionRests on an assumption: The DGAT2 degrader selectively degrades DGAT2 in vivo without off-target effects.

Probably not a substantial claim: may not pass S3 (load-bearing).

Dysregulation of lipids has been linked to neurodegenerative disorders, including AD.

“their dysregulation has been linked to neurodegenerative disorders, including AD24”

• cites [24] Wong, 2017, Dysregulation of lipids in Alzheimer’s disease and their role as potential biomarkers, Alzheimers Dement. sourceNot checked — no full text of the source

May combine two claims.

These findings identify a lipid-mediated mechanism underlying microglial dysfunction that could become a therapeutic target for AD.

“These findings identify a lipid-mediated mechanism underlying microglial dysfunction that could become a therapeutic target for AD.”

Classified as probably not a substantial claim.

Cellular lipids regulate functions like migration and phagocytosis.

“Cellular lipids regulate functions like migration and phagocytosis22”

• cites [22] Bourre, 2009, Brain lipids and ageing sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S4 (based). May combine two claims.

Triacylglycerols constitute the major neutral lipid core of lipid droplets and are integral to their structure and function.

“Since TGs constitute the major neutral lipid core of LDs and are integral to their structure and function”

Classified as probably not a substantial claim.

DGAT enzymes catalyze the final rate-determining step in the biosynthesis of triacylglycerols.

“The diacylglycerol O-acyltransferase (DGAT) enzymes catalyze the final rate-determining step in the biosynthesis of TGs.”

Probably not a substantial claim: may not pass S3 (load-bearing).

The conversion of FFAs to triacylglycerols can occur via two major pathways: the glycerol phosphatase pathway or the monoacylglycerol pathway.

“The conversion of FFAs to TGs can occur via two major pathways involving several intermediates: 1) the glycerol phosphatase pathway or 2) the monoacylglycerol pathway”

• cites [49] Yen, 2008, Thematic review series: Glycerolipids. DGAT enzymes and triacylglycerol biosynthesis, J. Lipid Res. sourceNot checked — no full text of the source

May combine two claims.

Degrading DGAT2 profoundly reduced lipid droplet content and mitigated neuritic dystrophy as well as amyloid pathology even in chronically inflamed 11-24-month-old 5xFAD mice.

“Taken together, these findings demonstrate that degrading DGAT2 profoundly reduced LD content and mitigated neuritic dystrophy as well as amyloid pathology even in chronically inflamed 11–24-month-old 5xFAD mice”

May combine two claims.

A possible lipid droplet saturation mechanism exists, where DGAT2-mediated microglial lipid droplet formation occurs with prolonged amyloid exposure, but after a certain point additional Aβ exposure seems insufficient to drive further lipid droplet accumulation in microglia.

“These results suggest a possible LD saturation mechanism, where DGAT2-mediated microglial LD formation occurs with prolonged amyloid exposure, but after a certain point additional Aβ exposure seems insufficient to drive further LD accumulation in microglia.”

Classified as probably not a substantial claim. May combine two claims.

Phagocytosis is a major innate immune mechanism contributing to Aβ clearance, and its failure favors Aβ accumulation in the brain.

“Phagocytosis is a major innate immune mechanism contributing to Αβ clearance, and its failure favors Αβ accumulation in the brain.”

May combine two claims.

The DGAT2 pathway is a target for therapeutic intervention to reduce phagocytic impairment of microglia and promote amyloid clearance or limit amyloid accumulation and associated neuronal dystrophy in the AD brain.

“identified the DGAT2 pathway as a target for therapeutic intervention to reduce phagocytic impairment of microglia and promote amyloid clearance or limit amyloid accumulation and associated neuronal dystrophy in the AD brain”

Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

The study did not interrogate how molecules in addition to Aβ may promote lipid droplet formation, exactly how free fatty acids increase in microglia in response to Aβ exposure, or what other microglial functions may be affected by lipid droplet formation or reduction.

“We also did not interrogate how molecules in addition to Aβ may promote LD formation, or exactly how FFAs increase in microglia in response to Aβ exposure, or what other microglial functions may be affected by LD formation or reduction.”

May combine two claims.

Inhibiting ACSL1 is successful in reducing lipid droplets, but this enzyme converts FFAs to acyl-CoA, which is a key step in ATP generation; therefore, inhibiting ACSL1 leads to lipotoxicity through toxic FFA accumulation and metabolic failure due to impaired energy production.

“Similarly, inhibiting acyl-coA synthetase long-chain 1 (ACSL1), is successful in reducing LDs, but this enzyme converts FFAs to acyl-CoA, which is a key step in ATP generation that cells use as an energy source; therefore, inhibiting ACSL1 leads to lipotoxicity through toxic FFA accumulation and metabolic failure due to impaired energy production.”

Probably not a substantial claim: may not pass S3 (load-bearing).

Combination therapy with the DGAT2 inhibitor Ervogastat and Clesacostat, an inhibitor of ACC, was granted fast track designation by the FDA for the treatment of NASH with liver fibrosis, based on its favorable safety and tolerability profile in a Phase2a clinical trial.

“As such, combination therapy with the DGAT2 inhibitor Ervogastat and Clesacostat, an inhibitor of Acetyl-CoA Carboxylase (ACC, also a downstream rate-limiting enzyme in de novo lipogenesis) was granted fast track designation by the FDA for the treatment of non-alcoholic steatohepatitis (NASH) with liver fibrosis, based on its favorable safety and tolerability profile in a Phase2a clinical trial.86”

• cites [86] Calle, 2021, ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials, Nat. Med. sourceNot checked — no full text of the source

Probably not a substantial claim: may not pass S3 (load-bearing).

The specificity of IBA1 and PLIN2 staining was ensured with secondary antibody control images.

“The specificity of the IBA1 and PLIN2 staining was ensured with the secondary antibody control images shown in Fig. S2g.”

Probably not a substantial claim: may not pass S3 (load-bearing).

All experiments involving mice were performed in accordance with Purdue University's Institutional Animal Care and Use Committee (IACUC) guidelines under application number 1812001834.

“All experiments involving mice were performed in accordance with the Purdue University’s Institutional Animal Care and Use Committee (IACUC) guidelines under application number 1812001834.”

Probably not a substantial claim: may not pass S3 (load-bearing).

The experimental blank was modeled as an intercept sample to ensure comparisons were significant with respect to the blank.

“The experimental blank that was done with the injection media was modeled as an ‘intercept’ sample in the analysis to make certain that comparisons were significant with respect to the blank.”

Probably not a substantial claim: may not pass S3 (load-bearing).

Data collection was randomized for all experiments.

“Data collection was randomized for all experiments and experimenters were blinded for imaging and data analyses.”

Probably not a substantial claim: may not pass S3 (load-bearing).

Reactions were run in duplicate.

“Reactions were run in duplicate.”

Classified as probably not a substantial claim. May combine two claims.

NS control samples were obtained from cases without a neurological or psychiatric diagnosis, and no chronic systemic inflammatory or infectious condition.

“NS control samples were obtained from cases without a neurological or psychiatric diagnosis, and no chronic systemic inflammatory or infectious condition.”

Probably not a substantial claim: may not pass S3 (load-bearing).

Plaque-associated microglia have direct access to remove aggregated amyloid through phagocytosis.

“Plaque–associated microglia have direct access to remove aggregated amyloid through phagocytosis.”

May combine two claims.

Disrupting DGAT2 can be a highly effective strategy for promoting a protective role of microglia in AD, and possibly in other neurodegenerative diseases with excessive protein aggregation and lipid droplet deposition.

“Our study thus provides proof-of-principle that disrupting DGAT2 can be a highly effective strategy for promoting a protective role of microglia in AD, and possibly in other neurodegenerative diseases with excessive protein aggregation and LD deposition.”

Probably not a substantial claim: may not pass S3 (load-bearing).

Experimenters were blinded for imaging and data analyses.

“Data collection was randomized for all experiments and experimenters were blinded for imaging and data analyses.”

May combine two claims.

Inhibiting DGAT2 restored phagocytosis in 5xFAD microglia ex-vivo, suggesting that phagocytic dysfunction is a consequence, not a cause, of chronic lipid droplet accumulation.

“Importantly, inhibiting DGAT2 restored phagocytosis in 5xFAD microglia ex-vivo, suggesting that phagocytic dysfunction is a consequence, not a cause of chronic LD accumulation.”

May combine two claims.

DGAT2 is a promising target for AD compared to other lipid-droplet-reducing molecules, possibly without introducing systemic side-effects.

“highlight DGAT2 as a promising target for AD compared to other LD-reducing molecules, possibly without introducing systemic side-effects.”

• AssumptionRests on an assumption: Ongoing efforts to target DGAT2 therapeutically have encouraging safety and tolerability results.

Classified as probably not a substantial claim.

Size exclusion of speckles and artifacts ensured that only true lipid droplet particles were selected for visualization and quantification in the PLIN2 channel.

“This size exclusion of speckles and artifacts also ensured that only true LD particles were selected for visualization and quantification in the PLIN2 channel.”

May combine two claims.

DGAT2 is a promising target to restore microglial phagocytosis, and thereby decrease amyloid deposition, and protect neurons, possibly without requiring a protracted treatment regimen, and perhaps even in patients with advanced pathology.

“Therefore, we identified DGAT2 as a promising target to restore microglial phagocytosis, and thereby decrease amyloid deposition, and protect neurons, possibly without requiring a protracted treatment regimen, and perhaps even in patients with advanced pathology.”

Probably not a substantial claim: may not pass S3 (load-bearing).

The study did not directly test all possible treatment regimens or administration methods to degrade DGAT2 in vivo.

“This study did not directly test all possible treatment regiments or administration methods to degrade DGAT2 in vivo”

Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based). May combine two claims.

Lipid droplets are important organelles that cells use for energy storage and to buffer excess lipids, which can protect them against lipotoxicity, especially in the context of inflammation.

“After all, LDs are important organelles that cells use for energy storage and to buffer excess lipids, which can protect them against lipotoxicity, especially in the context of inflammation.”

May combine two claims.

Acute exposure of primary microglia to Aβ increases inflammatory cytokine secretion and phagocytic performance, while chronic exposure reduces phagocytosis and induces immune tolerance, as well as a metabolic shift from oxidative phosphorylation to glycolysis.

“Acute exposure of primary microglia to Aβ increased their inflammatory cytokine secretion and phagocytic performance, while chronic exposure reduced phagocytosis and induced immune tolerance, as well as a metabolic shift from oxidative phosphorylation to glycolysis77.”

• cites [77] Baik, 2019, A Breakdown in Metabolic Reprogramming Causes Microglia Dysfunction in Alzheimer’s Disease, Cell Metab. sourceNot checked — no full text of the source

May combine two claims.

LXR agonists reduce lipid droplet accumulation through enhanced cholesterol efflux and exhibit anti-inflammatory properties, but their concurrent promotion of lipogenesis also leads to adverse effects such as hepatic steatosis and hyperlipidemia.

“For example, liver X receptor (LXR) agonists reduce LD accumulation through enhanced cholesterol efflux and exhibit anti-inflammatory properties, but their concurrent promotion of lipogenesis also leads to adverse effects such as hepatic steatosis and hyperlipidemia.82,83”

• cites [82] Kirchgessner, 2016, Beneficial and Adverse Effects of an LXR Agonist on Human Lipid and Lipoprotein Metabolism and Circulating Neutrophils, Cell Metab. sourceNot checked — no full text of the source
• cites [83] Hua, 2023, Liver X receptors: From pharmacology to nanoparticle-based drug delivery, Eur. J. Pharmacol. sourceNot checked — no full text of the source